iBio, Inc.
IBIO · XNASCIK 1420720fmd_0PAHW94G1DRQ6KNV6T7QAZ6D1GManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2003 to Sep 30, 2026, 66 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | – | – | 1 | 1 | 0 | – | – | – | – |
| Gross profit | – | – | – | 1 | 1 | 2 | – | – | – | – |
| Research and development | 4 | 4 | 5 | 4 | 10 | 10 | 10 | 5 | 8 | 20 |
| Total operating expenses | 15 | 15 | 18 | 15 | 32 | 32 | 29 | 17 | 19 | 35 |
| Operating income | (14) | (14) | (16) | (14) | (31) | (30) | (29) | (17) | (19) | (35) |
| Interest expense | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other non-operating income (expense) | (2) | (2) | (2) | (2) | 8 | 0 | 0 | 1 | 0 | 2 |
| Income before taxes | – | – | – | – | – | – | – | – | (18) | (33) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (30) | (29) | (15) | (18) | (33) |
| Net income | (15) | (16) | (18) | (16) | (23) | (50) | (65) | (25) | (18) | (33) |
| Net income to common shareholders | (15) | (16) | (18) | (38) | (23) | (30) | (29) | – | (18) | (33) |